Sanofi (SNY)

41.25
0.85 2.10
NYSE : Health Technology
Prev Close 40.40
Open 40.98
Day Low/High 40.75 / 41.33
52 Wk Low/High 37.43 / 50.65
Volume 5.37M
Avg Volume 2.35M
Exchange NYSE
Shares Outstanding 2.58B
Market Cap 103.69B
EPS 1.70
P/E Ratio 22.20
Div & Yield 1.20 (3.02%)
Dow Eyes 20,000 as Stocks Drift Higher

Dow Eyes 20,000 as Stocks Drift Higher

Stocks rise on Friday, putting the Dow Jones Industrial Average one step closer to the psychologically important 20,000 level.

5 Things You Must Know Before the Market Opens Friday

5 Things You Must Know Before the Market Opens Friday

U.S. stock futures are mixed while the dollar surges as global markets adjust to higher U.S. interest rates; Facebook plans to fact-check its news; Adobe's earnings top forecasts.

European Stocks Drift Lower; Dollar Dominates Global Financial Markets

European Stocks Drift Lower; Dollar Dominates Global Financial Markets

European stocks are set to book another solid weekly advance amid global market adjustments to the new Fed outlook.

Actelion Stock Hits Record High on Speculation of Sanofi Takeover Approach

Actelion Stock Hits Record High on Speculation of Sanofi Takeover Approach

Actelion stocks surged higher in Zurich amid speculation that France's Sanofi may make a formal approach for the Swiss biotech.

Johnson & Johnson Looks for New Deal That's Just Right

Johnson & Johnson Looks for New Deal That's Just Right

Actelion was too pricey. Now J&J is looking for another acquisition.

J&J Is Being Disciplined by Abandoning Merger Talks With Actelion, Jim Cramer Says

J&J Is Being Disciplined by Abandoning Merger Talks With Actelion, Jim Cramer Says

Jim Cramer comments on Johnson & Johnson's move to abandon merger talks with Actelion.

5 Things You Must Know Before the Market Opens Wednesday

5 Things You Must Know Before the Market Opens Wednesday

U.S. stock futures are mixed ahead of a decision on interest rates and fresh economic forecasts from the Fed; tech giants meet with Donald Trump; IBM's Rometty promises jobs.

Actelion Shares Plunge After J&J Drops Potential $27 Billion Takeover

Actelion Shares Plunge After J&J Drops Potential $27 Billion Takeover

Actelion confirms the end of talks with J&J over a $27 billion takeover, and market focus shifts to France's Sanofi.

European Stocks Fall as Investors Take Cautious Stance Ahead of Fed Meeting

European Stocks Fall as Investors Take Cautious Stance Ahead of Fed Meeting

European stocks are set to open lower Wednesday ahead of the Fed's final policy meeting of 2016.

5 Things You Must Know Before the Market Opens Tuesday

5 Things You Must Know Before the Market Opens Tuesday

U.S. stock futures trade flat following another record close for the Dow; Amazon reportedly envisions opening 2,000 brick-and-mortar grocery stores; Apple Watch sales set a record, Apple CEO says.

European Stocks Slip Lower, Italy Gains in Mixed Start to Trading

European Stocks Slip Lower, Italy Gains in Mixed Start to Trading

European markets are set for a positive open Tuesday after Asia traders booked their best single-day gains in two weeks.

Actelion Surges on Report of Sanofi Challenge to J&J Takeover Bid

Actelion Surges on Report of Sanofi Challenge to J&J Takeover Bid

Actelion shares are on the rise again on reports of a potential counter-bid from France's Sanofi.

Sanofi Genzyme Announces Start Of Phase III Study Of Isatuximab For Relapsed And Refractory Multiple Myeloma

Sanofi Genzyme Announces Start Of Phase III Study Of Isatuximab For Relapsed And Refractory Multiple Myeloma

Sanofi Genzyme, the specialty care global business unit of Sanofi, today announced the initiation of the ICARIA-MM Phase III trial of isatuximab, an investigational anti-CD38 monoclonal antibody being studied for the...

Actelion Shares Fall Sharply on Report It Is Resisting $17 Billion J&J Takeover

Actelion Shares Fall Sharply on Report It Is Resisting $17 Billion J&J Takeover

Actelion shares traded sharply lower Tuesday following reports it's looking at strategies that would keep it independent from a $17 billion approach from Johnson & Johnson.

Amicus Tumbles on Lengthy Delay to U.S. Fabry Drug FDA Filing Plan

Amicus Tumbles on Lengthy Delay to U.S. Fabry Drug FDA Filing Plan

The U.S. Food and Drug Administration turned down Amicus' request to seek accelerated approval for Galafold based on an existing kidney biomarker data.

Dow, Lifted by Financials, Finishes at Record High; Nasdaq Slips

Dow, Lifted by Financials, Finishes at Record High; Nasdaq Slips

Wall Street runs at two speeds as a rally in financials sent the Dow Jones Industrial Average to close at records, while a selloff in tech sank the Nasdaq.

Dow Hits New Records, Nasdaq Falls as Tech Stocks Decline

Dow Hits New Records, Nasdaq Falls as Tech Stocks Decline

Wall Street remains divided on Thursday as investors try to gauge the types of policies president-elect Donald Trump could enact.

MannKind Is Still Too Heavy to Avoid the Afrezza Crash Landing

MannKind Is Still Too Heavy to Avoid the Afrezza Crash Landing

MannKind bulls -- the rainbow-hued unicorns of the investment world -- believe the company's marketing efforts will succeed. They're wrong.

Here's Which Pharma Giants Might Want to Buy Pfizer's Consumer Health Unit

Here's Which Pharma Giants Might Want to Buy Pfizer's Consumer Health Unit

A sale or spinoff of this business will likely get the attention of competitors that want to increase their over-the-counter product units.

S&P 500, Nasdaq Turn Red in Erratic Post-Election Trading

S&P 500, Nasdaq Turn Red in Erratic Post-Election Trading

Wall Street runs at two speeds on Thursday with the Dow Jones Industrial Average setting a record high and the S&P 500 and Nasdaq slipping.

Stock Futures Rise as Wall Street Rally Continues After Trump's Win

Stock Futures Rise as Wall Street Rally Continues After Trump's Win

Stock futures move higher on Thursday with the Dow Jones Industrial Average set to open at a high.

Donald Trump Election Victory Boosts Some Stocks and Sectors

Donald Trump Election Victory Boosts Some Stocks and Sectors

As we all know, the stock market and the economy abhor uncertainty.

The Likely Market Impact of President Trump

As we all know, the stock market and the economy abhor uncertainty.

The Likely Market Impact of President Trump

As we all know, the stock market and the economy abhor uncertainty.

5 Things You Must Know Before the Market Opens Wednesday

5 Things You Must Know Before the Market Opens Wednesday

Stock futures are tumbling Wednesday but are well off their lows as Republican Donald Trump is elected the next president of the United States in a surprising victory.

European Drug Companies Get an Injection From Trump Victory

European Drug Companies Get an Injection From Trump Victory

The threat of a government clampdown on drug prices is off the table with Clinton's defeat, while wider support for defensive stocks helped push pharmaceuticals higher.

Gilead Sciences' Next Challenge to Incyte's Myelofibrosis Drug Dominance

Gilead Sciences' Next Challenge to Incyte's Myelofibrosis Drug Dominance

Gilead Sciences is nearing the completion of two phase III studies of the Jak inhibitor momelotinib in myelofibrosis, a disease affecting bone marrow.

Alexion Soars, Then Falls Amid Takeover Rumors

Alexion Soars, Then Falls Amid Takeover Rumors

The biotech company cancelled its conference appearance and took its time filing its Form 10-Q with the Securities and Exchange Commission.

Sanofi Genzyme Begins Pivotal Phase 3 Trial Of NeoGAA Investigational Second-Generation Therapy For Pompe Disease

Sanofi Genzyme Begins Pivotal Phase 3 Trial Of NeoGAA Investigational Second-Generation Therapy For Pompe Disease

Sanofi Genzyme, the specialty care global business unit of Sanofi, announced today that the first patient has been enrolled and received an infusion in a pivotal Phase 3 clinical trial named COMET for the...

The Internet of Things Is Transforming Healthcare, but There's One Huge Risk

The Internet of Things Is Transforming Healthcare, but There's One Huge Risk

Tech giants, Big Pharma and insurers are all angling to profit from the $3 trillion-plus U.S. healthcare market.

TheStreet Quant Rating: B (Buy)